Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2025-11-14 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about the schedule of upcoming analyst and institutional investor meetings. It explicitly states that no unpublished price sensitive information will be disclosed and provides dates and venues for these meetings. There is no financial data, report, or detailed presentation included. The document is an announcement of meetings rather than a report or transcript of the meetings themselves. Given the nature of the content, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-11-14 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation: Q2 FY26' and is dated November 14, 2025. It contains detailed financial and operational information for the second quarter of fiscal year 2026, including revenue figures, business highlights, strategic partnerships, and forward-looking statements. The text explicitly mentions it is an investor presentation and includes detailed financial data and business updates typical of such presentations. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a brief announcement or a regulatory filing but a comprehensive presentation aimed at investors. Therefore, the appropriate classification is 'Investor Presentation' (IP).
2025-11-14 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release and Management Discussion & Analysis (MD&A) for the second quarter ended September 30, 2025, of Glenmark Pharmaceuticals Limited. It contains detailed financial results, including revenue, EBITDA, and PAT figures, along with commentary from the Chairman & Managing Director. The document also includes a comprehensive review of operations, regional updates, product launches, and strategic partnerships. The presence of detailed financial data and management commentary for a quarterly period indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is consistent with a substantive financial report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2025-11-14 English
Outcome of Board Meeting
Regulatory Filings
2025-11-14 English
General Updates
Legal Proceedings Report Classification · 95% confidence The document is a formal letter addressed to stock exchanges and regulatory bodies, disclosing information about legal proceedings involving the company Glenmark Pharmaceuticals Limited. It details the nature of antitrust and consumer protection lawsuits, settlements reached, and the resolution of these litigations. The letter is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to material events or information. The content focuses on legal proceedings updates rather than financial results, management changes, or other report types. It is not a full audit report or annual report but a regulatory disclosure about ongoing legal matters. Therefore, the document fits best under the category of Legal Proceedings Report (LTR). The document length and detail support this classification with high confidence.
2025-11-14 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Glenmark Pharmaceuticals Limited addressed to stock exchanges, informing about the approval of their product RYALTRIS® by the National Medical Products Administration (NMPA) of China. It includes details about the product, clinical trial results, and market expansion plans. The document is dated November 10, 2025, and is structured as a press release or media release attached to the letter. There are no financial statements, regulatory certifications, or detailed financial data present. The document is not a report itself but an announcement of a significant corporate development related to product approval and market expansion. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement informing the market and stakeholders about a material event that does not fall under more specific categories.
2025-11-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.